Asia appears to be global center for counterfeit, substandard drugs

06/16/2013 | Economic Times (India), The

Asia, particularly China and India, appears to be the chief source of what the World Health Organization now labels "substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medicines." The global market for such fake drugs could be in the range of $50 billion to $200 billion, according to several reports, although authorities point out that large pharmaceutical firms, with export markets and reputations to protect, are rarely the problem.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA